Idiopathic thrombocytopenia purpura (ITP) is the destruction of platelets in the body. Autoimmune hemolytic anemia (AIHA) is a rare disease characterized by the body’s premature destruction of red blood cells (hemolysis). Both of these conditions are autoimmune disorders, which means that the body’s immune system malfunctions and attacks healthy blood cells. These two disorders can occur at the same time (destruction of both red blood cells and platelets) or one disorder develops after the other. Evans syndrome is the combination of AIHA with ITP. The cause of Evans syndrome is currently unknown.
A Phase 2 clinical study of an investigational drug is seeking AIHA patients who meet certain criteria.
Active, but not recruiting